Table 2.

Demographic and clinical characteristics compared between patients that survived and that died within 30 days (n = 206^a).

Characteristics	Survived	Deceased	p-Value
	(n = 183)	(n = 23)
Age (years)	63 (54–72)	76 (61–82)	.028
Age ≥65 years	79 (43.2%)	17 (73.9%)	.006
Female gender	101 (55.2%)	9 (39.1%)	.146
Comorbid disease	145 (79.2%)	20 (87.0%)	.008
Diabetes mellitus	73 (39.9%)	10 (43.5%)	.741
Solid malignancy	34 (18.6%)	7 (30.4%)	.180
Heart disease	26 (14.2%)	0 (0.0%)	.053
Chronic kidney disease	18 (9.8%)	6 (26.1%)	.022
Chronic liver disease	15 (8.2%)	3 (13.0%)	.438
Neurological disorder	11 (6.0%)	2 (8.7%)	.618
Chronic lung disease	6 (3.3%)	0 (0.0%)	.378
Immunosuppressive agent	3 (1.6%)	1 (4.3%)	.375
Autoimmune disease	3 (1.6%)	0 (0.0%)	.536
Hematologic malignancy	1 (0.5%)	1 (4.3%)	.080
Bedridden state	7 (3.8%)	3 (13.0%)	.053
Bacteraemia	131 (71.6%)	22 (95.7%)	.013
Clinical manifestations
Skin and soft tissue infection	61 (33.3%)	3 (13.0%)	.047
Primary bacteraemia	36 (19.7%)	7 (30.4%)	.231
Septic arthritis	43 (23.5%)	2 (8.7%)	.105
Meningitis	10 (5.5%)	3 (13.0%)	.159
Pneumonia	4 (2.2%)	9 (39.1%)	<.001
Osteomyelitis	13 (7.1%)	0 (0.0%)	.187
Infective endocarditis	9 (4.9%)	0 (0.0%)	.277
Eye infection	2 (1.1%)	0 (0.0%)	.614
Urinary tract infection	0 (0.0%)	1 (4.3%)	.005
Endometritis	1 (0.5%)	0 (0.0%)	.722
Chorioamnionitis	1 (0.5%)	0 (0.0%)	.722
Polymicrobial infections	35 (19.1%)	7 (30.4%)	.205
Morbidities	57 (31.1%)	23 (100%)	<.001
Shock	17 (9.3%)	13 (56.5%)
Renal failure	17 (9.3%)	4 (17.4%)
Respiratory failure	5 (2.7%)	4 (17.4%)
Others	18 (9.8%)	2 (20.9%)
Duration of treatment (days)	21 (14–44)	7 (1–14)	.015

Data reported as median and interquartile range (IQR) or number and percentage.

Bold p-values indicate statistical significance.

^aA total of 206 patients were included in this analysis because 18 patients were excluded (15 were referred and 3 against advice).